About Entheon

Entheon will utilize proprietary science, research and methodology to ensure addiction and mental health challenges no longer seems like an impossible, unending road.

We will ensure that when you or your loved one goes into recovery, you fully expect it
will work; redefining the expectations of addiction treatment.
.

Mission Statement

.

Entheon is powered by an unwavering commitment to significantly improve the odds of beating addiction for people who otherwise might not.
.

REASONS TO BELIEVE

THE RIGHT INTENTION

Entheon’s founders share a direct and personal understanding of the endless suffering and loss of human potential that comes with unsuccessful attempts to treat a disorder that has proven highly resistant to existing therapeutic models.

THE RIGHT PARTNERS

Entheon is collaborating with leaders in the psychedelic medicine space, in Canada and around the world. The meaningful inputs of our research and academic partners are validating our process, guiding our clinical trials and optimising the safety and efficacy of our product design.

THE RIGHT MOLECULE

Well tolerated with few adverse effects, pure DMT is the ideal molecule for advancing new models of psychedelic-assisted therapy. DMT is unique among hallucinogens in that it is endogenous in the human body. While other drugs in the class produce intense effects that last up to 12 hours, the effects of DMT are more gradual, less jarring and much shorter in duration.

THE RIGHT TECHNOLOGY

Our unique proposed delivery system titrates DMT into the body allowing for a gradual, more comfortable transition to the psychedelic state. The ability to control the duration and intensity of DMT’s effects, along with the ability to rapidly end the experience, will allow clinicians to provide the therapeutic effects of hallucinogens in a safer, more controlled and patient-specific manner.

THE RIGHT PATIENT EXPERIENCE

Our nuanced, individualized approach considers every aspect of the patient journey, including how the individual is informed and prepared, the comfort and ambiance of their treatment environment, and, following the psychedelic event, how they integrate the experience through talk therapy and post-care.

Meet The Team

Management

Timothy Ko

Timothy Ko

Chief Executive Officer

Brandon Schwabe, CPA, CGA

Brandon Schwabe, CPA, CGA

Chief Financial Officer

 

 

 

Andrew Hegle, PhD

Andrew Hegle, PhD

Director of Operations & Chief Science Officer

Dr. Brian Jahns

Dr. Brian Jahns

Chief Business Officer

 

 

 

 

 

Yaron Eshel

Yaron Eshel

Project Manager

 

 

 

Christopher Gondi, PhD

Christopher Gondi, PhD

Board Member

 

 

 

Ruth Chun, M.A., J.D.

Ruth Chun, M.A., J.D.

Board Member

 

 

 

 

 

Advisory Board

Professor Matthew W. Johnson, PhD

Professor Matthew W. Johnson, PhD

Scientific Advisor

Robin Carhart-Harris, PhD

Robin Carhart-Harris, PhD

Scientific Advisor

Dr. Dennis McKenna

Dr. Dennis McKenna

Scientific Advisor

Dr. Michael Walker

Dr. Michael Walker

Scientific Advisor

Christopher Timmermann, PhD

Christopher Timmermann, PhD

Scientific Advisor

Malin Vedøy Uthaug, PhD

Malin Vedøy Uthaug, PhD

Scientific Advisor

Kenneth W. Tupper, PhD

Kenneth W. Tupper, PhD

Advisor of Ethics

Nancy Maher

Nancy Maher

Special Advisor of Data Science and Regulatory Affairs

Dr. Dinesh Bhayana

Dr. Dinesh Bhayana

Scientific Advisor

Legal Team

DuMoulin Black

DuMoulin Black

Corporate Finance / M&As

Zuber Lawler

Zuber Lawler

Patents & IP

Partnerships

HaluGen Life Sciences Inc.

A wholly-owned subsidiary of Entheon, HaluGen Life Sciences is a biotech company that has developed a pre-screening test to identify genetic markers predictive of an individual’s reaction to hallucinogenic drugs, the “Psychedelics Genetic Test.

Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test

Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences

Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.

Psygen

Psygen is a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications, including psilocybin, MDMA, DMT, LSD, 2C-B, and mescaline.

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen.

CHDR

The Centre for Human Drug Research (CHDR) is an independent institute that specializes in cutting-edge early-stage clinical drug research. Combining innovative methods and technologies, state-of-the-art facilities, and talented, motivated researchers helps CHDR maximize their clients' success. In addition, CHDR places the highest priority on their subjects' comfort and safety, and they play an active role in helping educate the medical and clinical research communities. In addition, CHDR utilizes the services of the GMP-compliant the Leiden University Medical Center (LUMC). The LUMC pharmacy prepares and delivers the pharmaceutical products, including investigational medicinal products, and offers tailor-made solutions to help answer our sponsors' questions.

Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021

Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments

Science in Action

Based out of Ness Ziona, Israel, Science in Action (SIA) is a preclinical contract research organization (CRO) founded in 2010 by immunologist Raanan Margalit. SIA is GLP-accredited for toxicology studies in multiple areas, with extensive experience in tailor-made preclinical research in in-vivo and in-vitro models.

Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study

Heading Health

Founded in Austin, Texas, Heading Health provides a full-suite of therapies and diagnostic tools, including Spravato® (esketamine) nasal spray and Intramuscular (IM) ketamine designed to target depression, anxiety, PTSD and OCD indications. The Heading Health management team is experienced in operating and scaling psychiatric clinics across multiple states, securing insurance coverage and pioneering the most efficient and effective breakthroughs in clinical research and technologies.

Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC

Divergence Neuro

A Toronto-based company focused on the research and development of a data-driven, cloud-based neuro platform based on EEG-analysis and machine learning to improve mental health for all. Divergence's platform and research enhance clinical and personal mental health assessments by supplementing self-reporting methods with an easy-to-understand, cloud-based EEG software platform, offering individualized neurofeedback protocols driven by machine learning and AI combined with therapist interaction.

Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Ofichem Group

For over 40 years the Ofichem Group has been working to improve health for humans and animals by providing high quality Active Pharmaceutical Ingredients. API's that not only meet client's needs but also comply with stringent health and safety regulations.

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group